• Advances in the Understanding of Etiology (I)
• 30 min
  1. Infection and autoimmunity: a two-way relationship

  • Dr. Ricard Cervera
• 35 min
  2. Autoimmunity and atherosclerosis

  • Prof. Johan Frostegard
• 47 min
  3. Endothelium and autoimmunity

  • Prof. Pier Luigi Meroni
• Advances in the Understanding of Etiology (II)
• 22 min
  4. Prolactin has a pathogenic role in systemic lupus erythematosus

  • Prof. Luis Jara-Quezada
• 44 min
  5. Sjögren's syndrome: current knowledge and future prospects

  • Prof. Athanasios G. Tzioufas
• 51 min
  6. Genetic and environmental triggers of autoimmune thyroid diseases

  • Prof. Yaron Tomer
• Advances in Pathogenesis and Clinical Manifestation
• 38 min
  7. The catastrophic antiphospholipid syndrome and the microangiopathic antiphospholipid syndrome

  • Prof. Ronald Asherson
• 20 min
  8. Pathogenic mechanisms of autoantibodies: circulating and local antibodies that form immune complexes

  • Dr. Luís Eduardo Coelho Andrade
• 34 min
  9. Pathogenic mechanisms of autoantibodies: antibodies to intracellular and membrane-bound antigens

  • Dr. Luís Eduardo Coelho Andrade
• 43 min
  10. What causes primary biliary cholangitis?

  • Dr. M. Eric Gershwin
• 30 min
  11. Capillaroscopy in autoimmune rheumatic diseases

  • Prof. Maurizio Cutolo
• Advances in Diagnostic Methodologies (I)
• 26 min
  12. The past, present & future of ANA testing: history and challenges of ANA

  • Prof. Marvin J. Fritzler
• 33 min
  13. The past, present & future of ANA testing: changing bandwidth and future of ANA

  • Prof. Marvin J. Fritzler
• 36 min
  14. Diagnostic methods in autoimmunity

  • Mr. Steven Binder
• 24 min
  15. Systemic lupus erythematosus: novel aspects of pathogenesis and treatment 1

  • Prof. Chaim Putterman
  • Dr. Noa Schwartz
• 28 min
  16. Systemic lupus erythematosus: novel aspects of pathogenesis and treatment 2

  • Prof. Chaim Putterman
  • Dr. Noa Schwartz
• 48 min
  17. Novel aspects of systemic sclerosis

  • Prof. Gabriele Valentini
• Advances in Diagnostic Methodologies (II)
• 46 min
  18. An update on the multiple faces of celiac disease

  • Prof. Aaron Lerner
• 23 min
  19. Protective autoantibodies

  • Prof. Elias Toubi
• 32 min
  20. CD44 genetic deletion enhances and CD44 antibody targeting attenuates autoimmune inflammation

  • Prof. David Naor
• 44 min
  21. Rheumatic fever: a model of a post-infectious autoimmune disease

  • Prof. Jorge Kalil
• Treatments of autoimmune diseases
• 38 min
  22. Intravenous immunoglobulins: clinical evidence

  • Prof. Shaye Kivity
• Latest Developments in the Field
• 26 min
  23. Adjuvants and autoimmunity

  • Dr. Eitan Israeli
• 46 min
  24. Antiphospholipid syndrome (APS): from pathogenesis to treatment

  • Prof. Roger Levy
• 24 min
  25. Vitamin D and autoimmunity

  • Dr. Shir Azrielant
• 28 min
  26. Pregnancy in rheumatic diseases

  • Prof. Pier Luigi Meroni
• Archived Lectures *These may not cover the latest advances in the field
• 47 min
  27. Pathogenic mechanisms of autoantibodies

  • Prof. Cees Kallenberg
• 41 min
  28. B lymphocytes on the frontline of autoimmunity

  • Prof. Pierre Youinou
• 42 min
  29. Apoptotic cell clearance deficiency

  • Prof. Martin Herrmann
• 34 min
  30. Auto-antibodies as predictors of autoimmune disease

  • Dr. Nicola Bizzaro
• 46 min
  31. Innate immunity and natural autoantibodies

  • Prof. Luc Mouthon
• 45 min
  32. Accelerated atherosclerosis in autoimmune rheumatic disease

  • Dr. Andrea Doria
• 47 min
  33. Pregnancy in autoimmune rheumatic diseases

  • Prof. Angela Tincani
• 42 min
  34. Pulmonary hypertension in the connective tissue disease pathogenesis, clinical features and therapeutic options in 2006

  • Prof. Ronald Asherson
• 39 min
  35. Use of algorithms for high quality diagnostics and handling of patients with autoimmune rheumatic diseases

  • Dr. Allan Wiik
• 24 min
  36. Immunologic mechanisms in systemic lupus erythematosus

  • Prof. Kok-Yong Fong
• 23 min
  37. Osteoimmunology

  • Prof. João Eurico Fonseca
  • Ms. Joana Caetano-Lopes
• 43 min
  38. ANCA-associated systemic vasculitides

  • Prof. Loic Guillevin
• 23 min
  39. The common origin for diverse autoimmune diseases

  • Prof. Juan-Manuel Anaya
• 76 min
  40. Anti-cytokine therapy in rheumatoid arthritis

  • Prof. Piercarlo Sarzi-Puttini
• 40 min
  41. Sjogren's syndrome: autoimmune epithelitis

  • Prof. Haralampos Moutsopoulos
• 31 min
  42. Vitamin D and autoimmunity

  • Dr. Howard Amital
• 25 min
  43. Intravenous immunoglobulins: myth and reality

  • Prof. Zera Tellier

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Atherosclerosis (ATS)
3. Pathogenetic steps in atherosclerosis
4. Triggers and common pathway in atherosclerosis
5. Features of innate and adaptive immunity in ATS
6. Innate immunity factors involved in inflammatory
7. CRP distribution within the atherosclerotic plaque
8. CRP is a predictor of cardiovascular diseases
9. Unstable carotid plaque (CARS)
10. CD4+CD28null cells are expanded in angina
11. CD4+CD28null lymphocytes are pro inflammatory
12. CD4+CD28null in rheumatoid arthritis patients
13. CD4+CD28null cells and increased IMT
14. Atherosclerosis and autoimmunity
15. Role of oxLDL in foam cells formation
16. Anti-oxLDL and atherosclerosis
17. Protective and pathogenetic anti-oxLDL
18. Antiphospholipid antibodies
19. Structure of beta-2GPI
20. Surface charge and binding of beta-2GPI
21. Beta-2GPI as a target for APL Abs
22. Formation of oxLDL and beta-2GPI complex
23. oxLDL/beta-2GPI as an inflammation marker
24. The role of beta-2GPI in atherogenesis
25. beta-2GPI localization in atherosclerotic plaques
26. Immunization with beta-2GPI
27. Antiphospholipid antibodies in ATS patients
28. Example: protective role of anti-phospholipid Abs
29. Human heat-shock proteins (HSP)
30. Anti-heat shock protein (HSP) 60/65 antibodies
31. Enhanced ATS and associated factors in ARD
32. Atherosclerosis in RA - historical view
33. Coronary artery disease in RA patients
34. Coronary artery disease in SLE patients
35. Incidence of MI in SLE patients
36. Risk factors for atherosclerosis in SLE
37. Non-invasive techniques for detection of ATS
38. Duplex ultrasonography
39. Intima-media thickness (IMT) in RA patients
40. Risk factors for cardiovascular events
41. Parallelism between RA and atherosclerosis
42. Carotid ultrasound studies in SLE
43. Traditional and other metabolic risk factors for ATS
44. Cardiovascular risk in lupus
45. Novel risk factors for atherosclerosis
46. CRP and subclinical atherosclerosis in SLE
47. The relationship between autoantibodies and ATS
48. Subclinical atherosclerosis in SLE: study design
49. M-IMT and IgG anti-oxLDL levels - correlation
50. Mid conclusions
51. Questions which should be addressed
52. Correlates of accelerated atherosclerosis in SLE
53. Who are at highest risk for accelerated ATS?
54. Risk factors for carotid plaques in SLE
55. 78 SLE patients
56. PRD cumulative dosage in different patients
57. PRD dosage - adjusted for traditional risk factors
58. The bimodal mortality pattern of SLE
59. Long-term prognosis in SLE
60. Long-term prognosis in severe vs. mild SLE
61. Take home message
62. Conclusions
63. Role of the endothelium in vascular homoeostasis
64. Assessment of endothelial function
65. Ultrasonography of brachial artery
66. Endothelial dysfunction as predictor of CV events
67. Endothelial dysfunction in autoimmune diseases
68. Why does this correlation exist?
69. Distant effects of local vascular inflammation
70. Acknowledgments

Topics Covered

• Immunoinflammatory mechanisms involved in atherosclerosis
• Autoantibodies and atherosclerosis
• Clinical and subclinical atherosclerosis in rheumatoid arthritis
• Clinical and subclinical atherosclerosis in systemic lupus erythematosus
• Traditional and non-traditional risk factors for atherosclerosis in autoimmune rheumatic diseases
• Assessment of endothelial function in autoimmune rheumatic diseases
• Endothelial dysfunction in autoimmune rheumatic diseases

Links

Series:

• Autoimmunity

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on May 31, 2018

Financial Disclosures

• Dr. Andrea Doria has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.